Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

Figures

• 

  Fig. 1. Flow diagram of the included PAI-1 studies for meta-analysis

• 

  Fig. 2. Comparison of mean PAI-1 antigen levels (ng/mL) in patients with major adverse cardiac events and control patients. Data is expressed as a mean difference and analyzed using a random effects model

• 

  Fig. 3. Comparison of mean PAI-1 activity levels (IU/mL) in patients with major adverse cardiac events and control patients. Data is expressed as a mean difference and analyzed using a random effects model

• 

  Fig. 4. Comparison of mean PAI-1 antigen levels (ng/mL) in patients with primary and secondary major adverse cardiac events and control patients. Data is expressed as a mean difference and analyzed using a random effects model. a PAI-1 levels (ng/mL) in patients with primary major adverse cardiac events. b PAI-1 levels (ng/mL) in patients with secondary major adverse cardiac events

• 

  Fig. 5. Comparison of mean PAI-1 antigen and activity levels in patients with restenosis and control patients. Data is expressed as a mean difference and analyzed using a random effects model. a Comparison of mean PAI-1 antigen levels (ng/mL) in patients with restenosis. b Comparison of mean PAI-1 activity levels (IU/mL) in patients with restenosis

• 

  Fig. 6. Comparison of risk of major adverse cardiac events in patients stratified by PAI-1 antigen levels (ng/mL). Data is expressed as a risk ratio and analyzed using a random effects model